Could gene therapy someday eliminate HIV?

January 3, 2018 by Alan Mozes, Healthday Reporter

(HealthDay)—Gene therapy may have the potential to eradicate HIV in people infected with the virus, new animal research suggests.

The science centers around the use of "chimeric antigen receptor" (CAR) genes. In laboratory work with monkeys, these engineered have destroyed HIV-infected cells for more than two years, scientists reported.

"Theoretically, the goal is to provide a lifelong immunity to HIV," said study co-author Scott Kitchen, of the University of California, Los Angeles, School of Medicine.

"We're aiming for a cure," he said. "And we know that to cure HIV you need an effective , which is what we're seeing here." Kitchen is an associate professor of medicine with the division of hematology and oncology.

Scientists have been searching for a way to create long-term immunity to HIV, the AIDS-causing virus. Currently, is prescribed to keep HIV under control, but this doesn't eliminate the virus from the body.

Kitchen explained the new strategy this way: "In terms of basic immunology, T-cells are the cells that are largely responsible for our ability to fight off pathogens and get rid of infections in the body. Malignancies. Anything abnormal.

"Every T-cell has a unique receptor, or molecule, on it. That receptor allows the cell to recognize a specific target—a bacteria, or fungus or virus. And when it recognizes that target, it's called into duty to clear it from the body," Kitchen said.

"What we've done is to take artificial receptors—or CAR—that can go on to these cells and allow them to recognize what we want them to recognize," he noted. "In this case that's HIV."

The goal is to develop "a reverse vaccination, in which we engineer an immune response to target HIV," he added.

The concept of engineering chimeric antigen receptors dates back about 20 years, according to Kitchen. And CAR T-cell therapy has been touted as a treatment for a range of cancers.

"That's a good thing, because it means we already know it's safe," he said.

What's new is the research team's dual use of stem cells and CAR to target a form of HIV.

Credit: CC0 Public Domain

First, the team genetically engineered CAR to find and bind to simian/human immunodeficiency virus (SHIV), a lab-engineered HIV hybrid composed of human virus and monkey virus.

Then the researchers modified the DNA of certain so they would carry SHIV-killing CAR.

The resulting cells were introduced into the bloodstream of four male juvenile SHIV-infected macaque monkeys.

The engineered cells successfully took up residence in each monkey's bone marrow. The cells moved widely throughout the body, targeting and killing SHIV-infected cells, without producing any notable adverse side effects, the researchers reported.

"The advantage of the stem cell-based approach is that once these cells are grafted into the body, they continuously produce new T-cells that have this gene in them that can target HIV cells," Kitchen explained.

Plans are underway for a human trial, which should get going within two to three years, Kitchen said.

"There is, of course, a big leap to be made when you go from animal studies to human studies," he cautioned. However, "this study shows both that these cells will respond to HIV and that it's safe."

Also, this strategy is unlikely to fully work on its own, Kitchen added, noting that "HIV is highly complex. So there's not really going to be one silver bullet."

Kitchen said CAR will most likely need to be used alongside antiretroviral therapy.

Marcella Flores is associate director of research for amfAR (The Foundation for AIDS Research), which helped fund the study. She expressed both enthusiasm and caution.

"CAR therapy is already leading to impressive results in cancer and holds promise for HIV eradication," she noted.

However, Flores stressed that the current study conditions "do not represent 'real life' conditions." While these monkey studies have important implications for human outcomes, she said the results in humans may be quite different.

The study results were published in the Dec. 28 issue of PLOS Pathogens.

Explore further: Gene therapy using CAR T-cells could provide long-term protection against HIV

More information: Scott G. Kitchen, Ph.D., associate professor, medicine, division of hematology and oncology, David Geffen School of Medicine, University of California, Los Angeles; Marcella Flores, MPH, Ph.D., associate director, research, amfAR (The Foundation for AIDS Research), New York City; Dec. 28, 2017, PLOS Pathogens

There's more on HIV at the U.S. National Institute of Allergy and Infectious Diseases.

Related Stories

Gene therapy using CAR T-cells could provide long-term protection against HIV

December 28, 2017
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. ...

Stem cell gene therapy holds promise for eliminating HIV infection

July 1, 2015
cientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are one step closer to engineering a tool that could one day arm the body's immune system to fight HIV—and win. The new technique ...

Using viruses to fight viruses: New approach eliminates 'dormant' HIV-infected cells

December 18, 2017
While Ottawa researchers are known for their work on cancer-fighting viruses, one team is applying these viruses to a new target: HIV.

Engineered stem cells seek out, kill HIV in living organisms

April 12, 2012
(Medical Xpress) -- Expanding on previous research providing proof-of-principal that human stem cells can be genetically engineered into HIV-fighting cells, a team of UCLA researchers have now demonstrated that these cells ...

Protein that activates immune response harms body's ability to fight HIV

December 23, 2016
In findings they call counterintuitive, a team of UCLA-led researchers suggests that blocking a protein, which is crucial to initiating the immune response against viral infections, may actually help combat HIV.

A new method for removing cells infected with the AIDS virus

October 2, 2017
With the successful suppression of the AIDS virus (HIV) through medication, the focus turns toward its eradication. Researchers from Kumamoto University in Japan have developed a new compound that is key to the destruction ...

Recommended for you

Long-acting injectable implant shows promise for HIV treatment and prevention

October 9, 2018
A persistent challenge in HIV/AIDS treatment and prevention is medication adherence – getting patients to take their medication as required to get the best results.

Scientists develop rapid test for diagnosing tuberculosis in people with HIV

October 8, 2018
An international team that includes Rutgers scientists has made significant progress in developing a urine diagnostic test that can quickly, easily and inexpensively identify tuberculosis infection in people also infected ...

Researchers uncover new role of TIP60 protein in controlling tumour formation

October 8, 2018
Scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have discovered a new molecular pathway that controls colorectal cancer development, and their exciting ...

Combination therapy targets latent reservoir of HIV

October 3, 2018
With more than 35 million people worldwide living with the virus and nearly 2 million new cases each year, the human immunodeficiency virus (HIV) remains a major global epidemic. Existing antiretroviral drugs do not cure ...

Anti-integrin therapy effect on intestinal immune system in HIV-infected patients

October 3, 2018
In a study published today in Science Translational Medicine, Mount Sinai researchers describe for the first time a mechanism that may shrink collections of immune cells in the gastrointestinal (GI) tract, called lymphoid ...

No 'reservoir': Detectable HIV-1 in treated human liver cells found to be inert

October 1, 2018
In a proof-of-principle study, researchers at Johns Hopkins report that a certain liver immune cell called a macrophage contains only defective or inert HIV-1 copies, and aren't likely to restart infection on their own in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.